

IMPACT OF SERUM LEVELS OF AFP ON RESPONSE TO TREATMENT IN GENOTYPE 4 CHRONIC HCV PATIENTS

**Thesis Submitted in fulfillment for the Master Degree in
Tropical Medicine**

BY

AISHA MAHMOUD ABDEL-AZIZ

M.B.B.Ch

SUPERVISORS

PROF. DR. SAMEH LABIB

**Professor of Tropical Medicine
Faculty of Medicine - Cairo University**

PROF. DR. OLFAT SHAKER

**Professor of Medical Biochemistry
Faculty of Medicine - Cairo University**

DR. MAISSA EL RAZIKY

**Assistant Professor of Tropical Medicine
Faculty of Medicine - Cairo University**

**Faculty of Medicine
Cairo University
2007**

3/4→Z«O3/4Àl«Y2 ^c1z^«3/4^ °«Y1/2 c€°«YzAgc
í ÓñîŸ ÈçàÊç í Öñã í Yî?UãÉÊËÖç
-]Yz«Y3/4À«YŽ°`«Y2 - "1/4• 2 - |°«Y

رسالة مقدمة من

|ç|~«V^—u° °p~`„ΛZ—

توطئة للحصول على درجة الماجستير
فى طب المناطق الحارة

تحت اشراف

\ Å«n7Z. u

أستاذ الأمراض المتوطنة
كلية الطب- جامعة القاهرة

z§ Z b / «Ou

أستاذ الكيمياء الحيوية
كلية الطب- جامعة القاهرة

1/4£{Yz° «Y €zZ -

أستاذ مساعد الأمراض المتوطنة
كلية الطب- جامعة القاهرة

كلية الطب- جامعة القاهرة

2007

ABSTRACT

Therapy of chronic hepatitis C has greatly improved in recent years, especially with the addition of ribavirin to interferon and with the use of PEG-IFN with ribavirin. Although AFP is used as a diagnostic marker of HCC, mild elevation can be seen in virus related acute and chronic hepatitis.

Aim of work: To detect the relation between the level of AFP in chronic HCV patients and degree of fibrosis and inflammation of the liver and to use AFP to predict SVR to combined interferon therapy.

Participants and methods: 175 chronic HCV patients: 91 patients received PEG-IFN α 2b and ribavirin and 84 patients received IFN α 2b and ribavirin for 48 weeks, for them routine investigations, serum AFP level and liver biopsy prior to treatment were done.

Results: High serum AFP is correlated with older age, low serum albumin level, low platelet count, higher stage of fibrosis and high HAI index, AFP appears as an additional tool to predict SVR to combined IFN therapy.

Key words: AFP – treatment of HCV – Predictors of response to HCV treatment.

ACKNOWLEDGEMENT

*“He, and will always be, Allah who always blessed my work
And who sent me those who were of help “*

I would like to thank ALLAH a lot for his kindness, patience and strength he gave to me to achieve this work and made me able to finish it.

I am greatly honored to express my deep gratitude and faithfulness to Dr. Sameh Labib, Professor of Tropical Medicine, Cairo University. He gave me his valuable advices and support that cannot be expressed in words. His fatherhood attitude and encouragement were so supportive for the completion of this work.

My deep thanks and appreciation to Dr. Maissa EL-Raziky, Assistant Professor of Tropical Medicine, Cairo University, for her strict supervision and revision of this work, She gave me much of her time, experience and support, her valuable comments, efforts and collaboration were the causes to complete this work properly, so no words can express my gratitude to her.

I would like to thank Dr. Olfat Shaker, Professor of Medical Biochemistry, Cairo University, for her kindness, sympathy, generous help, goodness, sincere encouragement and patience with me.

I am extremely grateful to Dr. Gamal Esmat, Professor of Tropical Medicine, Cairo University for his sincere guidance and his help and support throughout the work. To him therefore, I express my deep sense of gratitude.

Very special thanks to Dr. Wafaa El-Akel, she never let me down and she was always standing by me when I needed her help and advice.

I would like to thank all my staff members of the Tropical Medicine Department, Cairo University, especially Dr. Serag Zakaria the head of the department for his continuous guidance, encouragement and support for me and my colleagues.

My deep thanks to all my colleagues, all patients included in this work and every one made any effort for this work to be a reality.

A special dedication to my family for their never ending care. They were always supporting me and encouraging me to continue and finish this work,

Aisha El-Sharkawy

TABLE OF CONTENTS

Introduction and aim of the work.....	1
Review of literature.....	
- <u>Part I:</u> Alpha fetoprotein.....	5
- <u>Part II:</u> Treatment of HCV.....	22
Participants and Methods.....	59
Results.....	65
Discussion.....	92
Summary and Conclusions.....	100
Recommendations.....	103
References.....	104
.....	



Yt **Y**

LIST OF TABLES

Table I	Side effects of interferon and ribavirin	41
Table 1a	Demographic features of the studied patients	65
Table 1b	Sex distribution of the studied patients	65
Table 2	Risk factors for hepatitis in the studied patients	66
Table 3	The biochemical profile of the studied patients prior to therapy	67
Table 4	PCR results of the studied patients	68
Table 5	SVR of the studied patients	68
Table 6	Inflammatory activity of the studied patients	69
Table 7	Fibrosis stage of the studied patients	69
Table 8	Degree of steatosis of the studied patients	70
Table 9	Alpha fetoprotein (AFP) level of the studied patients prior to therapy	71
Table 10	AFP level (x ULN) of the studied patients	72

Table 11	Age versus AFP level in the studied patients	72
Table 12	Risk factors versus AFP in the studied patients	73
Table 13	Biochemical profile versus AFP level in the studied patients	74
Table 14	CBC versus AFP level in the studied patients	75
Table 15	HBc Ab versus AFP level in the studied patients	76
Table 16	Rectal snip versus AFP level in the studied patients	77
Table 17	HAI versus AFP level of the studied patients	78
Table 18	Fibrosis versus AFP level of the studied patients	79
Table 19	Steatosis versus AFP level of the studied patients	80
Table 20	Nonparametric correlation between AFP level and other parameters	81
Table 21	Results of INF therapy versus AFP level	87
Table 22	Results of INF therapy in relation to type of treatment and level of AFP	88

LIST OF FIGURES

Figure 1	Risk factors for hepatitis in the studied patients	66
Figure 2	Alpha fetoprotein (AFP) level of the studied patients prior to therapy	71
Figure 3	Age versus AFP level in the studied patients	72
Figure 4	Biochemical profile versus AFP level in the studied patients	74
Figure 5	CBC versus AFP level in the studied patients	75
Figure 6	HBc Ab versus AFP level in the studied patients	76
Figure 7	HAI versus AFP level of the studied patients	78
Figure 8	Fibrosis versus AFP level of the studied patients	79
Figure 9	Steatosis versus AFP level of the studied patients	80
Figure 10	Correlation between serum AFP level (xULN) and age of the patients	82
Figure 11	Correlation between AFP level (xULN) and platelets count of the patients	83

Figure 12	Correlation between AFP level and both of ALT (xULN) and bilirubin levels in the studied patients	84
------------------	--	----

Figure 13	Correlation between AFP level and AST and ALT level of the studied patients	85
Figure 14	Correlation between AFP levels and both of HAI and fibrosis in biopsies of the studied patients	86
Figure 15	Results of INF therapy versus AFP level	87
Figure 16	Results of IFN therapy in relation to type of treatment and level of AFP.	89
Figure 17	ROC curve for AFP level in Relation to Response to TTT.	90
Figure 18	ROC curve for AFP and Fibrosis in Relation to Response to TTT.	91

LIST OF ABBREVIATIONS

- **AASLD:** American Association for the Study of Liver Diseases
- **AFP:** Alpha fetoprotein
- **AFP-L :** Alpha fetoprotein-lectin
- **ALT:** Alanine aminotransferase
- **DDB:**Dimethyl-4, 4'-dimethoxy-5,6,5',6'dimethylene dioxymbiohenyl-2, 2'-dicarboxylate
- **dsRNA:** double-stranded RNA
- **EVR:** early virological response
- **GGT:** Gamma glutamyl transaminase
- **GTP:** Gamma transpeptidase
- **HAI:** Histological activity index
- **HBcAb:** Hepatitis B core antibody.
- **HBsAg:** Hepatitis B surface antigen
- **HCC:** Hepatocellular carcinoma
- **HCV:** Hepatitis C virus
- **HDC:** Histamine dihydrochloride
- **HP:** Hepatocyte proliferation
- **IFN:** Interferon
- **IL:** Interleukin
- **IMPDH:** inosine 5'-monophosphate dehydrogenase
- **IMU:** International million unit
- **INR:** International normalized ratio
- **IRES:** internal ribosome entry site
- **LCA:** lectin lens culinaris agglutin
- **LPS:** Lipopolysaccharide

- **MMP:** Matrix metalloproteases
- **mPEG:** monomethoxy polyethylene glycol
- **mRNA:** Messenger RNA
- **NF Kappa B:** nuclear factor-Kappa B
- **NIH:** National Institutes of Health
- **NK:** Natural killer cell
- **NS:** Non structural
- **NSGCT:** non-seminomatous germ cell tumours
- **NS5B:** Non structural 5 B
- **PEG-IFN:** Pegylated interferon
- **PPV:** positive predictive value
- **RIA:** radioimmunoassay
- **RNA:** Ribonucleic acid
- **RNAi:** RNA interference
- **RTPCR:** reverse-transcription polymerase chain reaction
- **siRNAs:** Small interfering RNAs
- **SOD:** superoxide dismutase
- **SVR:** sustained virologic response
- **Th1:** T – helper 1
- **Th2:** T – helper 1
- **TNF:** Tumour necrotic factor
- **Tα -1:** Thymosin alpha 1

INTRODUCTION

Hepatitis C is a major cause of liver related morbidity and mortality worldwide and represents a major public health problem (*Alberti and Benvegnu, 2003*). Chronic infection occurs in 50-80% of cases and eventually leads to cirrhosis and hepatocellular carcinoma (*Pawlotsky, 2004*). Genotype distribution varies considerably from country to country, with genotype 4 prevailing in Africa and the Middle East (*Hoofnagle, 2002*).

Egypt has possibly the highest HCV prevalence worldwide (*Pybus et al., 2003*). Overall prevalence of antibody to HCV in the general population is around 15-20% (*Frank et al., 2000*). The overall prevalence of anti-HCV antibody in semirural and rural Egyptian communities was 20.7%, and the prevalence in each type of communities was 23% and 17.9% respectively (*Zakaria et al., 2000*).

Arthur et al. (1997) found that HCV seroprevalence in different governorates ranged from zero to 38%. The seroprevalence of HCV increased with age, from 19% in persons 10 – 19 years old to about 60% in persons 30 years and older (*Darwish et al., 2001*).

Therapy of chronic hepatitis C has greatly improved in recent years. Rates of sustained virological response have increased significantly in the late 1990s with the addition of ribavirin to interferon and have further

improved more recently with the use of PEG-IFN again in combination with ribavirin (*Alberti and Benvegna, 2003*).

Alberti et al. (1993) confirmed that pretreatment alanine aminotransferase (ALT) and γ -glutamyl transpeptidase levels tend to be lower in responders. *Poynard et al. (1998)* reported five factors associated with a favorable response: genotype 2 or 3, viral load less than 2 million copies per ml, age less than 40 years, minimal fibrosis on biopsy, and female sex.

Alpha fetoprotein (AFP) is a typical onco-developmental glycoprotein with one asparagine N-linked oligosaccharide (*Katsuko et al., 1993*). It is synthesized mainly in fetal life by yolk sac and in trace amounts by the fetal GIT. It is therefore normally present in the fetus and disappears a few weeks after birth. AFP forms one third of the total fetal plasma proteins. Carrying out most of the functions described to albumin in the adult life (*Kaneko et al., 2001*). The normal adult serum AFP concentration does not exceed 6ng/ml (*Greenberg, 1990*).

Significant synthesis of AFP commences again when some adult cell becomes transformed to cancer cells, AFP is also produced by the differentiated adult hepatocytes. The differentiation of the cancer cells and genetic depression of protein synthesis would explain the AFP production by cancer cells (*Johnson, 2001*).

AFP and liver ultrasonography are the most widely used tools for screening of hepatocellular carcinoma (*Barletta et al., 2005*).

Serum AFP values are elevated among patients with advanced HCV. Factors associated with raised AFP include severity of liver disease, female gender and black race. Serum AFP levels decline during antiviral therapy (*Di Bisceglie et al., 2005*).

In patients with chronic HCV, elevated serum AFP levels were significantly correlated with lower serum albumin levels, advanced fibrosis/cirrhosis and genotype 1b infection (*Chu et al., 2001*).